• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床实践中的因子 Xa 抑制剂:药代动力学特征比较。

Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.

机构信息

Department of Cardiology and Nephrology, Dokkyo Medical University, 880-Kitakobayashi, Mibu, Tochigi, 321-0293, Japan.

Internal Medicine, NHO Tochigi Medical Center, 1-10-37 Naka-Tomatsuri, Utsunomiya, Tochigi, 320-8580, Japan.

出版信息

Drug Metab Pharmacokinet. 2020 Feb;35(1):151-159. doi: 10.1016/j.dmpk.2019.10.005. Epub 2019 Oct 25.

DOI:10.1016/j.dmpk.2019.10.005
PMID:32007354
Abstract

BACKGROUND

The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be inferred from their observed plasma concentrations; however, the steady-state pharmacokinetics (PK) of different FXa inhibitors have not been compared in clinically.

METHODS

The sensitivity of the rivaroxaban, apixaban, and edoxaban in the STA-Liquid Anti-FXa assay were compared, and the anti-FXa plasma concentrations were measured for PK assessments. Nonlinear mixed-effects modeling was used to assess population PK in 329 patients with nonvalvular atrial fibrillation or venous thromboembolism. Patients were followed up for an average of 3.6 years.

RESULTS

Sensitivity was similar among the three drugs in this assay, which could directly compare plasma concentrations instead of anti-FXa activities. Overall exposure was greatest in 5 mg BID apixaban relative to other drugs (p < 0.001). The geometric mean AUC for the 0 to 24-h interval was 4550 ng h/mL for apixaban, 2710 ng h/mL for 15 mg QD rivaroxaban, and 1290 ng h/mL for 60 mg QD edoxaban. The PKs of 2.5 mg BID apixaban or 15 mg QD rivaroxaban were associated with hemorrhagic events.

CONCLUSIONS

Apixaban was associated with greater exposure, higher trough concentrations in plasma compared with rivaroxaban or edoxaban. Furthermore, a higher plasma concentration may partially predict hemorrhagic events.

摘要

背景

口服直接因子 Xa(FXa)抑制剂的抗凝作用可以从其观察到的血浆浓度推断出来;然而,不同 FXa 抑制剂的稳态药代动力学(PK)尚未在临床上进行比较。

方法

比较了利伐沙班、阿哌沙班和依度沙班在 STA-Liquid Anti-FXa 测定中的敏感性,并测量了抗-FXa 血浆浓度以进行 PK 评估。非线性混合效应模型用于评估 329 例非瓣膜性心房颤动或静脉血栓栓塞患者的群体 PK。患者平均随访 3.6 年。

结果

在该测定中,这三种药物的敏感性相似,因此可以直接比较血浆浓度而不是抗-FXa 活性。与其他药物相比,5mg BID 阿哌沙班的总体暴露量最大(p<0.001)。阿哌沙班 0 至 24 小时间隔的几何平均 AUC 为 4550ng·h/mL,15mg QD 利伐沙班为 2710ng·h/mL,60mg QD 依度沙班为 1290ng·h/mL。2.5mg BID 阿哌沙班或 15mg QD 利伐沙班的 PK 与出血事件相关。

结论

与利伐沙班或依度沙班相比,阿哌沙班的暴露量更大,血浆中的谷浓度更高。此外,较高的血浆浓度可能部分预测出血事件。

相似文献

1
Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.临床实践中的因子 Xa 抑制剂:药代动力学特征比较。
Drug Metab Pharmacokinet. 2020 Feb;35(1):151-159. doi: 10.1016/j.dmpk.2019.10.005. Epub 2019 Oct 25.
2
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs.三种口服因子 Xa 抑制剂的微剂量鸡尾酒,以评估与潜在肇事药物的药物相互作用。
Clin Pharmacokinet. 2019 Sep;58(9):1155-1163. doi: 10.1007/s40262-019-00749-1.
3
Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.采用超高效液相色谱-串联质谱法测定大鼠血浆中利伐沙班、阿哌沙班和依度沙班的含量。
J Thromb Thrombolysis. 2016 Aug;42(2):205-11. doi: 10.1007/s11239-016-1367-y.
4
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.一所综合医院中接受治疗的老年日本房颤患者使用抗凝剂阿哌沙班、达比加群、依度沙班和利伐沙班的药代动力学
Xenobiotica. 2019 Sep;49(9):1001-1006. doi: 10.1080/00498254.2018.1524188. Epub 2018 Dec 11.
5
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.采用低分子肝素校准的抗因子 Xa 测定法来评估阿哌沙班和利伐沙班的浓度。
Int J Lab Hematol. 2022 Feb;44(1):163-167. doi: 10.1111/ijlh.13692. Epub 2021 Sep 15.
6
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.伴有肝损伤的患者应用口服直接因子 Xa 抑制剂利伐沙班、阿哌沙班和依度沙班以及凝血酶抑制剂达比加群酯的抗凝治疗。
Clin Pharmacokinet. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0.
7
Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.真实世界中抗 Xa 口服抗凝药血浆浓度测定:使用低分子肝素校准品对急诊中利伐沙班和阿哌沙班进行定量分析。
Ann Pharmacother. 2019 Apr;53(4):341-347. doi: 10.1177/1060028018811657. Epub 2018 Oct 31.
8
Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.每日一次利伐沙班和每日两次阿哌沙班的药代动力学和药效学分离:一项随机交叉研究。
J Thromb Haemost. 2017 Oct;15(10):2017-2028. doi: 10.1111/jth.13801. Epub 2017 Sep 14.
9
Effect of Clarithromycin, a Strong CYP3A and P-glycoprotein Inhibitor, on the Pharmacokinetics of Edoxaban in Healthy Volunteers and the Evaluation of the Drug Interaction with Other Oral Factor Xa Inhibitors by a Microdose Cocktail Approach.克拉霉素对健康志愿者中依度沙班药代动力学的影响及其通过微剂量鸡尾酒法评估与其他口服 Xa 因子抑制剂的药物相互作用。
Cardiovasc Drugs Ther. 2024 Aug;38(4):747-756. doi: 10.1007/s10557-023-07443-2. Epub 2023 Mar 4.
10
Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.接受阿哌沙班或利伐沙班治疗的患者的抗Xa活性比较。
Ann Pharmacother. 2018 Mar;52(3):251-256. doi: 10.1177/1060028017738262. Epub 2017 Oct 19.

引用本文的文献

1
Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.接受血液透析的终末期肾病合并心房颤动患者中阿哌沙班的群体药代动力学建模
Clin Pharmacokinet. 2025 Feb;64(2):307-321. doi: 10.1007/s40262-025-01476-6. Epub 2025 Jan 24.
2
Antithrombotic therapy and the risk of pocket hematoma after subcutaneous implantable cardioverter-defibrillator implantation.皮下植入式心脏复律除颤器植入术后的抗栓治疗与囊袋血肿风险
J Interv Card Electrophysiol. 2025 Jan 16. doi: 10.1007/s10840-024-01973-x.
3
Establishment of an Integrated Population Pharmacokinetic/ Pharmacodynamics Model of Apixaban in Chinese Healthy Population Adjusting for Key Genetic Variants.
建立考虑关键基因变异因素的阿哌沙班在中国健康人群中的整合群体药代动力学/药效学模型。
Curr Pharm Des. 2025;31(9):716-729. doi: 10.2174/0113816128306062241007053405.
4
Population pharmacokinetics of rivaroxaban in Chinese deep vein thrombosis patients and the exposure simulation for dosing recommendation.利伐沙班在中国深静脉血栓患者中的群体药代动力学及剂量推荐的暴露模拟。
Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):3351-3362. doi: 10.1007/s00210-023-02798-7. Epub 2023 Nov 11.
5
Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale.凝血酶原复合物浓缩物对接受Xa因子抑制剂治疗且发生大出血或需要紧急手术的患者凝血酶生成的影响(GAUGE):设计与原理
TH Open. 2023 Jul 25;7(3):e229-e240. doi: 10.1055/s-0043-1771300. eCollection 2023 Jul.
6
Safety of endoscopic ultrasound-guided tissue acquisition with uninterrupted direct oral anticoagulation in a swine model.猪模型中持续直接口服抗凝治疗下内镜超声引导组织获取的安全性
Endosc Int Open. 2023 Apr 28;11(4):E413-E418. doi: 10.1055/a-2016-0160. eCollection 2023 Apr.
7
Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations.已发表的阿哌沙班和利伐沙班群体药代动力学模型对肥胖静脉血栓栓塞症治疗患者的适用性:一项系统评价与外部评估
Pharmaceutics. 2023 Feb 16;15(2):665. doi: 10.3390/pharmaceutics15020665.
8
Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban.亚洲人是否需要较低剂量的利伐沙班?利伐沙班群体药代动力学和药效学分析的系统评价。
Pharmaceutics. 2023 Feb 9;15(2):588. doi: 10.3390/pharmaceutics15020588.
9
Rationale and design of a prospective study evaluating population pharmacokinetics and pharmacodynamics of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.评价非瓣膜性心房颤动中国患者利伐沙班群体药代动力学和药效学的前瞻性研究的原理和设计。
BMJ Open. 2022 Jun 3;12(6):e058378. doi: 10.1136/bmjopen-2021-058378.
10
Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease.依度沙班单药治疗合并冠状动脉疾病的非瓣膜性心房颤动患者。
J Interv Cardiol. 2022 Dec 17;2022:5905022. doi: 10.1155/2022/5905022. eCollection 2022.